Crystalline sodium (5R, 6S,
8R)-6-(1-hydroxyethyl)-2-(2-carbamoyloxyethylthio)-penem-3-carboxylate
and process for making same
    3.
    发明授权
    Crystalline sodium (5R, 6S, 8R)-6-(1-hydroxyethyl)-2-(2-carbamoyloxyethylthio)-penem-3-carboxylate and process for making same 失效
    结晶钠(5R,6S,8R)-6-(1-羟乙基)-2-(2-氨基甲酰氧基乙硫基) - 庚-3-烯酸甲酯及其制备方法

    公开(公告)号:US4634556A

    公开(公告)日:1987-01-06

    申请号:US732533

    申请日:1985-05-10

    CPC分类号: C07D499/88

    摘要: A novel, stable, crystalline sodium (5R,6S,8R)-6-(1-hydroxyethyl)-2-(2-carbamoyloxyethylthio)-penem-3-carboxylate (designated as Form II) is prepared by forming a homogenous solution of sodium (5R,6S,8R)-6-(1-hydroxyethyl)-2-(2-carbamoyloxyethylthio)-penem-3-carboxylate combined with stirring the homogenous solution for a time and at a temperature sufficient to produce Form II and recovering Form II. Form II may also be prepared by contacting a first solution obtained by dissolving (5R,6S,8R)-6-(1-hydroxyethyl)-2-(2-carbamoyloxyethylthio)-penem-3-carboxylic acid in dimethylacetamide with a second solution obtained by dissolving a sodium salt of an organic acid having a pKa of up to about 5, e.g., sodium 2-ethylhexanoate in acetone, in the presence of at least 5 volume percent water while stirring the reaction mixture so formed at a temperature and for a time sufficient to produce Form II followed by recovering Form II.Form II exhibits a greater physical stability and increased solid state chemical stability and reduced hygroscopicity over that of the amorphous form (e.g., Form I) which renders Form II greatly superior to Form I as a clinically suitable antibacterial agent.

    摘要翻译: 通过形成均匀的溶液来制备新的稳定的结晶的(5R,6S,8R)-6-(1-羟乙基)-2-(2-氨基甲酰氧基乙硫基) - 庚-3-烯氧基化钠(命名为II型) 的(5R,6S,8R)-6-(1-羟乙基)-2-(2-氨基甲酰氧基乙硫基) - 庚-3-烯酰氧基化合物与搅拌均匀溶液一段时间并在足以产生II型 并恢复II型。 形式II也可以通过将通过将(5R,6S,8R)-6-(1-羟乙基)-2-(2-氨基甲酰氧基乙硫基) - 亚氨基-3-碳氧基酸溶解在二甲基乙酰胺中获得的第一溶液与第二溶液 通过在至少5体积%的水的存在下,将具有高达约5的pKa的有机酸的钠盐例如2-乙基己酸酯溶解在丙酮中而获得的溶液,同时搅拌在温度下形成的反应混合物, 一段时间足以生产II型,然后恢复II型。 II型具有更大的物理稳定性和增加的固态化学稳定性,并且比非晶形式(例如,形式I)的吸湿性降低,其使得II型作为临床合适的抗菌剂大大优于I型。